Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
RenovoRx, Inc. shareholders approved Election of Directors at the 2023-06-08 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
Proposal 1: Election of Directors Name of Director For Withheld Broker Non-Votes Ramtin Agah, M.D. 5,094,179 19,343 2,374,191 Shaun R. Bagai 5,094,179 19,343 2,374,191 David Diamond 5,107,063 6,459 2,374,191 Kirsten Angela Macfarlane 5,106,837 6,685 2,374,191 Laurence J. Marton, M.D. 5,068,635 44,887 2,374,191 Una S. Ryan, O.B.E., Ph.D., D.Sc. 5,053,096 60,426 2,374,191 Robert J. Spiegel, M.D., FACP 5,013,634 99,888 2,374,191 Each director nominee was duly elected to serve until the 2024 Annual Meeting of Stockholders and until their successor is duly elected and qualified, subject to their earlier resignation or removal.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
RenovoRx, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-06-08 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain Broker Non-Votes 7,463,474 22,982 1,257 0 The stockholders ratified the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
View on SEC.gov